Monday, September 09, 2019 7:57:37 AM
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aOGI-2807334&symbol=OGI®ion=C
ORGANIGRAM RECEIVES HEALTH CANADA APPROVAL TO BRING TOTAL LICENSED PRODUCTION CAPACITY TO TARGET OF 76,000 KG/YR
Effective Sept. 6, 2019, Organigram Holdings Inc. has received Health Canada's approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations.
The new cultivation rooms represent approximately 15,000 kilograms/year of increased target production capacity. These are the first 17 rooms licensed within the company's phase 4B expansion and now bring the company's Moncton facility to annualized licensed capacity to a target of 76,000 kg.
The licences are valid until March 27, 2020, and subject to terms and conditions.
"Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date. Our phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale," explained Greg Engel, chief executive officer, Organigram.
As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis commencing immediately. The company anticipates harvesting product from these new rooms by the end of November assuming normal cultivation timelines. After drying and other postharvest processing (including packaging) dried flower from these additional rooms is expected to be available for sale to patients and customers in the company's fiscal quarter ending Feb. 29, 2020.
Substantial construction of the entire phase 4B stage remains on schedule for completion in September, 2019, and the company also anticipates submitting the licensing amendment for the remaining 16 phase 4B cultivation rooms later this month.
The perimeter of phase 5 of the company's expansion, which will include an edibles and derivative product facility and more extraction capacity, is also planned for this Health Canada licensing submission.
Recent OGI News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/03/2024 01:30:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 01:29:42 PM
- Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment • Business Wire • 09/03/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 11:25:59 AM
- Organigram Reports Third Quarter Fiscal 2024 Results • Business Wire • 08/13/2024 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/07/2024 03:19:22 PM
- Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology • Business Wire • 08/07/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/06/2024 02:32:27 PM
- Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024 • Business Wire • 08/06/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 03:20:28 PM
- Organigram Announces Appointment of Craig Harris to Board of Directors • Business Wire • 07/29/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 09:06:57 PM
- Organigram to Bolster Auto-Flower and Rare Cannabinoid Portfolio with Partial Third Tranche Investment of US $1M into Phylos • Business Wire • 07/24/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2024 07:13:48 PM
- Organigram investe in Sanity Group, società leader tedesca nel settore della cannabis • Business Wire • 06/26/2024 01:15:00 PM
- Organigram investiert in Sanity Group, ein führendes deutsches Cannabisunternehmen • Business Wire • 06/26/2024 01:15:00 PM
- Organigram investit dans Sanity Group, un chef de file du cannabis en Allemagne • Business Wire • 06/26/2024 01:15:00 PM
- Organigram Invests in Sanity Group, a Leading German Cannabis Company • Business Wire • 06/25/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 01:38:30 PM
- Organigram Signs Three Year Supply Agreement with Avida Medical in UK • Business Wire • 05/28/2024 10:00:00 AM
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2024 11:17:16 AM
- Organigram Reports Second Quarter Fiscal 2024 Results • Business Wire • 05/14/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 03:29:51 PM
- Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024 • Business Wire • 05/08/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM